Drugs News and Research

RSS

Rifampicin resistant tuberculosis

Scientists have identified a strain of antibiotic-resistant tuberculosis that thrives in the presence of rifampin, a front-line drug in the treatment of tuberculosis. The bacterium was identified in a patient in China and is described in a study by researchers at the Johns Hopkins Bloomberg School of Public Health, Chongqing Pulmonary Hospital, Lanzhou University and Fudan University.

22 Dec 2009

Urigen Pharmaceuticals and Oceana Therapeutics jointly prepare for meeting with FDA on URG101

Urigen Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that the Company and Oceana Therapeutics have agreed to jointly prepare for a meeting with the U.S. Food & Drug Administration regarding the continued development of URG101.

22 Dec 2009

Findings may help develop new antiviral drugs for influenza

Investigators at Burnham Institute for Medical Research (Burnham), Mount Sinai School of Medicine (Mount Sinai), the Salk Institute for Biological Studies (Salk) and the Genomics Institute of the Novartis Research Foundation (GNF) have identified 295 human cell factors that influenza A strains must harness to infect a cell, including the currently circulating swine-origin H1N1.

22 Dec 2009

Clarient announces acquisition of Applied Genomics

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has acquired privately held, Huntsville, AL-based Applied Genomics, Inc. (AGI) in an all-stock merger valued at up to $17.6 million, if all conditions and milestones set forth in the merger agreement are successfully met.

21 Dec 2009

Response Biomedical receives USPTO Notice of Allowance for its “Sensitive Immunochromatographic Assay”

Response Biomedical Corporation announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a continuation of the patent entitled “Sensitive Immunochromatographic Assay”. This patent covers key aspects of Response Biomedical’s lateral flow immunoassays with the proprietary RAMP® testing platform.

21 Dec 2009

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

Isis Pharmaceuticals, Inc. today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and advanced non-small cell lung cancer.

21 Dec 2009

Investigation of IDH1 gene mutations in brain cancer receives new funds

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the emerging field of cancer metabolism, announced today that it has received funding from Accelerate Brain Cancer Cure (ABC2), a non-profit organization that supports brain cancer research. ABC2’s funding will enable new research investigating IDH1 gene mutations in brain cancer, with the goal of supplementing Agios’s ongoing research into the development of new IDH1 therapeutics and diagnostics.

21 Dec 2009

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Intra-Cellular Therapies, Inc. (ITI) announced at a recent conference on neuropsychiatric diseases the results from a recently completed Phase I clinical study demonstrating ITI-007, the Company's lead antipsychotic drug, interacts with important targets in the living human brain. These key targets are critical to drug action in many neuropsychiatric and related disorders.

21 Dec 2009

Seattle Genetics and GSK sign ADC collaboration agreement

Seattle Genetics, Inc., announced today that it has entered into a collaboration agreement with GlaxoSmithKline (GSK) under which GSK will pay an upfront fee of $12 million for rights to utilize Seattle Genetics’ antibody-drug conjugate (ADC) technology with multiple antigens to be named by GSK.

21 Dec 2009

EMEA grants orphan drug designation for pixantrone in Europe

Cell Therapeutics, Inc. ("CTI") announced today that the European Medicines Agency (EMEA) has granted pixantrone orphan drug designation for the treatment of DLBCL which accounts for about 80% of aggressive non-Hodgkin's lymphoma.

21 Dec 2009

Researchers follow steps that lead some tumor cells to establish metastases

Up to 25% of cancer patients develop metastases in the brain - often long after successful treatment of the primary tumor. In almost all such cases, the prognosis is poor. The mechanisms responsible for the appearance of brain metastases have long been mysterious.

21 Dec 2009

Malaria nasal vaccine, antimicrobial peptide against MRSA, and safer method to prolong orange juice shelf life

An experiemental nasally administered malaria vaccine prevented parasite transmission from infected mice to mosquitoes and could play an important role in the fight against human malaria. The researchers from Japan report their findings in the December 2009 issue of the journal Infection and Immunity.

19 Dec 2009

Children with type 1 diabetes benefit from rapid-acting insulin analogues; potential harm remains unclear

Due to a lack of suitable studies, it remains unclear whether children and adolescents with type 1 diabetes benefit more or less from long-term treatment with rapid-acting insulin analogues than with short-acting human insulin.

19 Dec 2009

Research lays hope for developing drugs that can control apoptosis

Walter and Eliza Hall Institute scientists have identified a key step in the biological process of programmed cell death, also called apoptosis.

19 Dec 2009

SCCA's infection control program leads to suppression of potential H1N1 pandemic

Despite a 100-fold increase in H1N1 influenza cases in the Seattle area during spring 2009, an aggressive infection control program to protect immunocompromised cancer patients and thorough screening measures resulted in no corresponding increase in H1N1 cases among the total patient population at the Seattle Cancer Care Alliance, according to a new study by researchers and physicians at Fred Hutchinson Cancer Research Center and the SCCA.

19 Dec 2009

Neogen reports record net income for second-quarter fiscal 2010

Neogen Corporation announced today that its net income for the second quarter of FY 2010, which ended Nov. 30, increased 18% from the previous year's second quarter. Adjusted for a 3-for-2 stock split effective Dec. 15, net income in the quarter rose to $0.20 per share, compared to the prior year's $0.17. Neogen's second quarter net income of $4,610,000 set another quarterly record for the 27-year-old company.

19 Dec 2009

Possible link between presence of breast cancer genes and infertility discovered

A New York Medical College physician who specializes in restoring or preserving fertility in female cancer patients has discovered a possible link between the presence of breast cancer genes and infertility.

19 Dec 2009

158 of American Oriental Bioengineering's drugs included in China's 2009 NIC

American Oriental Bioengineering, Inc., ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products, today announced that 158 of the Company's drugs have been included in China's National (Medical) Insurance Catalog (the "2009 NIC").

19 Dec 2009

KVCI completes acquisition of former AAIPharma bioanalytical division

Kansas Venture Capital, Inc. (KVCI) has acquired the former AAIPharma bioanalytical division from ZeeCRO Inc. With its 30-year track record of developing entrepreneurial companies, KVCI will grow the bioanalytical business through organic and acquisition strategies to provide best-in-class analytical services for both the pharmaceutical and life sciences sectors.

18 Dec 2009

U.S. health officials announce shift in focus of prep trial in Botswana

U.S. health officials on Thursday announced they will shift the focus of a clinical trial in Botswana aimed at testing pre-exposure prophylaxis (PrEP) - the strategy that "a daily low dose of the drugs, which interfere with the ability of the virus to replicate, could also lower the risk of infection" - after researchers discovered they would be unable to determine the efficacy of Truvada, the medicine used in the trial, Reuters reports.

18 Dec 2009

Drugs News and Research

Rifampicin resistant tuberculosis

Urigen Pharmaceuticals and Oceana Therapeutics jointly prepare for meeting with FDA on URG101

Findings may help develop new antiviral drugs for influenza

Clarient announces acquisition of Applied Genomics

Response Biomedical receives USPTO Notice of Allowance for its “Sensitive Immunochromatographic Assay”

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

Investigation of IDH1 gene mutations in brain cancer receives new funds

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Seattle Genetics and GSK sign ADC collaboration agreement

EMEA grants orphan drug designation for pixantrone in Europe

Researchers follow steps that lead some tumor cells to establish metastases

Malaria nasal vaccine, antimicrobial peptide against MRSA, and safer method to prolong orange juice shelf life

Children with type 1 diabetes benefit from rapid-acting insulin analogues; potential harm remains unclear

Research lays hope for developing drugs that can control apoptosis

SCCA's infection control program leads to suppression of potential H1N1 pandemic

Neogen reports record net income for second-quarter fiscal 2010

Possible link between presence of breast cancer genes and infertility discovered

158 of American Oriental Bioengineering's drugs included in China's 2009 NIC

KVCI completes acquisition of former AAIPharma bioanalytical division

U.S. health officials announce shift in focus of prep trial in Botswana

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News